ERT launches Virtual Visit solutions to keep clinical trials on track during COVID-19

ERT, a global data and technology company that captures critical endpoint data while minimising uncertainty and risk in clinical trials, announced a Virtual Visit solution that enables the continuation of clinical trials during and after current global stay-at-home mandates.

As a result of COVID-19, many clinical trials have been delayed as healthcare providers focus their efforts on patients who require urgent care, which limits clinical trial patients’ access to investigative sites for routine visits. In order to keep their studies on track, clinical trial sponsors and CROs need innovative solutions that enable investigative site personnel and patients to interact with each other, regardless of their physical location (often referred to as TeleHealth).

ERT’s Virtual Visit solution enables at-home consultations between patients and investigative site personnel via a seamless, dedicated, secure app or web interface. The offering allows patients to consult with their clinicians safely from home, simplifying their participation in clinical trials and enabling researchers to continue collecting the important safety and efficacy data needed to support their development objectives. The solution complements ERT’s suite of safety and efficacy data capture solutions, improving patient engagement throughout ongoing and new clinical trials.

“We’re pleased to offer another significant capability in a series of revolutionary virtual trial solutions to support our customers as they address the challenges presented by COVID-19,” said Matthew McCarty, Vice President, Digital Patient at ERT. “Our research indicates that nearly 80 per cent of the industry is shifting to virtual trial solutions during this unprecedented time and we remain committed to delivering the dynamic tools they need to continue their important, life-saving research,” he added.